Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

878
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
878
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer02:18

Cancer

53.3K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trifluridine/tipiracil (FTD/TPI) in advanced gastric cancer-a retrospective cohort study providing real-world survival and safety data from the United Kingdom.

Journal of gastrointestinal oncology·2026
Same author

High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma.

Cancer immunology, immunotherapy : CII·2024
Same author

Residual cancer cells after apparent complete pathological response to neoadjuvant therapy in oesophageal adenocarcinoma.

The British journal of surgery·2024
Same author

Selinexor Enhances NK Cell Activation Against Malignant B Cells <i>via</i> Downregulation of HLA-E.

Frontiers in oncology·2021
Same author

Gender differences in hepatitis C seroprevalence and suboptimal vaccination and hepatology services uptake amongst substance misusers.

Journal of medical virology·2012
Same author

The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival.

Cancer biology & therapy·2010
Same journal

Use of comprehensive geriatric assessment among oncologists in Uruguay: perceptions, practices and barriers.

Ecancermedicalscience·2026
Same journal

Age and sex-based differences in therapy preferences among patients with cancer: evidence from a novel therapy preference scale.

Ecancermedicalscience·2026
Same journal

Prospective evaluation of locoregional control in oral cavity squamous cell carcinoma with lower or mid infratemporal fossa involvement treated with surgery and adjuvant concurrent chemoradiotherapy.

Ecancermedicalscience·2026
Same journal

Trends in incidence and mortality of acute and chronic leukaemias in Brazil: challenges and advances over three decades.

Ecancermedicalscience·2026
Same journal

A scoping review on pathways/models/frameworks for palliative care provision for cancer patients while admitted at hospitals within sub-Saharan Africa.

Ecancermedicalscience·2026
Same journal

Cost-effectiveness and budget impact of breast cancer genetic profiling in Egypt.

Ecancermedicalscience·2026
See all related articles

Related Experiment Video

Updated: Dec 26, 2025

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

1.8K

elearning for cancer immunotherapy.

Samuel L Hill1, Peter Wm Johnson2

  • 1Clinical Academic Research Fellow, Medical Oncology Registrar, University of Southampton, Centre for Cancer Immunology, University Hospital Southampton (MP 127), Tremona Road, Southampton, SO16 6YD, UK.

Ecancermedicalscience
|March 11, 2020
PubMed
Summary
This summary is machine-generated.

Cancer immunotherapies, like immune checkpoint inhibitors, are increasingly used for advanced cancers. Enhanced knowledge through elearning for healthcare professionals is crucial for managing benefits and side effects.

Keywords:
checkpoint inhibitorselearningimmunotherapy

More Related Videos

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K

Related Experiment Videos

Last Updated: Dec 26, 2025

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

1.8K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K

Area of Science:

  • Oncology
  • Immunology

Background:

  • Cancer immunotherapy has advanced significantly with immune checkpoint inhibitors, expanding treatment for advanced cancers.
  • The growing use of these therapies necessitates increased healthcare professional (HCP) involvement in patient care.

Discussion:

  • While beneficial, immunotherapies do not benefit all patients and can cause significant toxicity.
  • Healthcare professionals require updated knowledge to effectively manage patients undergoing these treatments.

Key Insights:

  • Immune checkpoint inhibitors represent a major advance in cancer treatment.
  • Patient outcomes with immunotherapy vary, highlighting the need for careful management.
  • Elearning tools can improve HCP understanding of immunotherapy mechanisms, benefits, and adverse events.

Outlook:

  • Further development and integration of elearning are essential for supporting clinical staff.
  • Optimizing patient care through enhanced HCP education is a key future direction.